For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Vyndamax and Attruby represents a genuine breakthrough . These novel therapies stabilize the transthyretin protein, preventing its destructive build-up and alleviating the impact of the condition . People are now seeing positive